Dzmitry Sinitski

Feodor Lynen Str. 17
Munich, BY 81377, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Tuberculosis diagnosis and the complete drug resistance pattern from a single sample within a single day by use of a composite platform of MAX MDR-TB and AmPORE-TB.

Tuberculosis diagnosis and the complete drug resistance pattern from a single sample within a single day by use of a composite platform of MAX MDR-TB and AmPORE-TB.

Journal: Journal of clinical microbiology

Published: January 12, 2026

An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis.

An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis.

Journal: Nature communications

Published: January 24, 2024

Plant MDL proteins synergize with the cytokine MIF at CXCR2 and CXCR4 receptors in human cells.

Plant MDL proteins synergize with the cytokine MIF at CXCR2 and CXCR4 receptors in human cells.

Journal: Science signaling

Published: November 21, 2023

CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia.

CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia.

Journal: Experimental hematology

Published: July 30, 2021

Chemokine-like MDL proteins modulate flowering time and innate immunity in plants.

Chemokine-like MDL proteins modulate flowering time and innate immunity in plants.

Journal: The Journal of biological chemistry

Published: January 22, 2021

A MIF-Derived Cyclopeptide that Inhibits MIF Binding and Atherogenic Signaling via the Chemokine Receptor CXCR2.

A MIF-Derived Cyclopeptide that Inhibits MIF Binding and Atherogenic Signaling via the Chemokine Receptor CXCR2.

Journal: Chembiochem : a European journal of chemical biology

Published: August 16, 2020

Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting.

Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting.

Journal: Nature communications

Published: December 02, 2019

Studying Plant MIF/D-DT-Like Genes and Proteins (MDLs).

Studying Plant MIF/D-DT-Like Genes and Proteins (MDLs).

Journal: Methods in molecular biology (Clifton, N.J.)

Published: November 21, 2019

Cross-kingdom mimicry of the receptor signaling and leukocyte recruitment activity of a human cytokine by its plant orthologs.

Cross-kingdom mimicry of the receptor signaling and leukocyte recruitment activity of a human cytokine by its plant orthologs.

Journal: The Journal of biological chemistry

Published: June 07, 2019

Macrophage Migration Inhibitory Factor (MIF)-Based Therapeutic Concepts in Atherosclerosis and Inflammation.

Macrophage Migration Inhibitory Factor (MIF)-Based Therapeutic Concepts in Atherosclerosis and Inflammation.

Journal: Thrombosis and haemostasis

Published: February 05, 2019

Identification of an Arg-Leu-Arg tripeptide that contributes to the binding interface between the cytokine MIF and the chemokine receptor CXCR4.

Identification of an Arg-Leu-Arg tripeptide that contributes to the binding interface between the cytokine MIF and the chemokine receptor CXCR4.

Journal: Scientific reports

Published: October 03, 2017

Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo.

Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 16, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026